Description: Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Home Page: www.cellectis.com
8, rue de la Croix Jarry
Paris,
75013
France
Phone:
33 1 81 69 16 00
Officers
| Name | Title |
|---|---|
| Dr. Andre Choulika Ph.D. | Co-Founder, CEO & Director |
| Dr. David j. d. Sourdive Ph.D. | Deputy CEO, Executive VP of CMC & Manufacturing and Director |
| Mr. Arthur Stril | Interim Chief Financial Officer |
| Valerie Cros | Principal Financial Officer & Principal Accounting Officer |
| Mr. Jean Charles Epinat | Chief Technological Officer |
| Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer |
| Ms. Marie-Bleuenn Terrier | General Counsel & Secretary of the Board of Directors |
| Pascalyne Wilson | Director of Communications |
| Ms. Kyung Nam-Wortman | Executive VP & Chief Human Resources Officer |
| Mr. Stephan Reynier M.Sc. | Chief Regulatory & Pharmaceutical Compliance Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7108 |
| Price-to-Sales TTM: | 7.054 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 216 |